Journal profile · Oncology
LANCET ONCOLOGY
ISSN 1470-2045 · eISSN 1474-5488 · Lancet Publishing Group · UNITED STATES · Monthly · Founded 2000
LANCET ONCOLOGY: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 33.23; hybrid open access; APC about USD 7,280; median 62 days to acceptance (75 articles, last 24 months); community-reported acceptance: very hard; 503 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
LANCET ONCOLOGY is published by Lancet Publishing Group and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Global Cancer Incidence and Screening and Economic and Financial Impacts of Cancer, together about 19.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and academy centres). The journal is lively and informative, covering international issues relevant to clinical cancer specialties worldwide. Content covers topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine6.9%
- Global Cancer Incidence and ScreeningMedicine6.6%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance6%
- Advances in Oncology and RadiotherapyMedicine5.9%
- Cancer Immunotherapy and BiomarkersMedicine5.7%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.3%
- Prostate Cancer Treatment and ResearchMedicine4.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 33.23LetPub ·
- Impact factor (publisher)
- 33.7Publisher website ·
- CiteScore 2026-06
- 42LetPub ·
- CiteScore (publisher)
- 42Publisher website ·
- SJR 2026-06
- 9.43LetPub ·
- SNIP 2026-06
- 8.83LetPub ·
- h-index
- 274LetPub ·
- h-index
- 524OpenAlex ·
- i10-index
- 4,552OpenAlex ·
- 2-year mean citedness
- 12.17OpenAlex ·
- Self-citation rate
- 1.8%LetPub ·
- Share of gold OA articles
- 16.03%LetPub ·
Volume
- Articles per year
- 174LetPub ·
Articles by year OpenAlex count · 12,159 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 330 | 56 | 547 |
| 2025 | 503 | 118 | 5,007 |
| 2024 | 470 | 142 | 10,310 |
| 2023 | 420 | 145 | 15,902 |
| 2022 | 498 | 163 | 22,679 |
| 2021 | 499 | 152 | 45,504 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
62 daysMedian, submission to acceptance · P25–P75 18 days – 116 days
- Acceptance to online
- median 80 days (31 articles)
- Submission to online
- median 167 days
- Sample
- 75 articles with submission and acceptance dates (977 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- Very hardLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 34 daysPublisher website ·
- Submission to acceptance
- 34 daysPublisher website ·
- Acceptance to publication
- 80 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,280 / EUR 6,810 / GBP 5,830 / JPY 902,940 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lancet Publishing Group
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2000
- ISSN
- 1470-2045
- Electronic ISSN
- 1474-5488
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about LANCET ONCOLOGY
What CAS zone is LANCET ONCOLOGY in?
In the 2025 upgraded edition of the CAS Journal Ranking, LANCET ONCOLOGY is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of LANCET ONCOLOGY?
The latest impact factor listed by LetPub is 33.23; CiteScore 42, h-index 524.
How long does peer review take at LANCET ONCOLOGY?
Based on the dates recorded on 75 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 62 days (interquartile range 18–116 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Very hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index LANCET ONCOLOGY?
According to LetPub and DOAJ records, LANCET ONCOLOGY is indexed in SCIE and Scopus.
Is LANCET ONCOLOGY open access, and what is the APC?
LANCET ONCOLOGY is a hybrid journal. For open-access publication: APC about USD 7,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .